Pharmaceutical

Simtra BioPharma to invest more than $250m in US facility

Simtra BioPharma has announced plans invest $250m for an expansion of its sterile fill/finish manufacturing site in Bloomington, Indiana, US.

Mar 1, 2024 - 18:00
Simtra BioPharma to invest more than $250m in US facility
Simtra BioPharma has announced plans invest $250m for an expansion of its sterile fill/finish manufacturing site in Bloomington, Indiana, US.
Read the original article

Tags:

Previous Article

UK MHRA approves new formulation of Amgen’s XGEVA

Next Article

Rovi’s Expansion in Pharmaceutical Production with Moderna

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: We’re reading about kids taking Wegovy, telehealth for abortion pills, and more

STAT+: Pharmalittle: We’re reading about kids taking We...

Feb 17, 2024

Exscientia acquires oral CDK7 inhibitor for $20m, plans breast cancer trial

Exscientia acquires oral CDK7 inhibitor for $20m, plans...

Jul 20, 2024

NexImmune to lay off over half of its employees

NexImmune to lay off over half of its employees

Sep 1, 2023